Cas9 Stable Cell Line - KYSE-30

The KYSE-30 cell line is a mature human esophageal squamous cell carcinoma model, originally derived from a Japanese patient. These cells possess an epithelial morphology and are characterized by mutations in key oncogenes (such as TP53) and tumor suppressor genes, making them a valuable resource for studying the pathogenesis of esophageal cancer. The Cas9 Stable Cell Line - KYSE-30 is a genetically engineered variant in which the CRISPR-associated protein 9 (Cas9) endonuclease is stably integrated into the KYSE-30 genome. This modification allows for sustained Cas9 expression, ensuring the stability of gene-editing capabilities and avoiding the problem of low efficiency in transient transfection. This cell line retains the characteristics of the parental KYSE-30 cells, including proliferation rate, adhesion behavior, and tumorigenicity, while providing a powerful platform for precise genomic manipulation.

The Cas9 Stable Cell Line - KYSE-30 can accelerate functional genomics and therapeutic research in multiple fields. In cancer target discovery, it enables high-throughput CRISPR screening to identify genes driving esophageal cancer progression, metastasis, or drug resistance. Researchers can systematically knock out tumor suppressor genes (such as CDKN2A) or oncogenes (such as PIK3CA) to elucidate signaling pathways such as EGFR or PI3K/AKT. In drug development, this cell line can mimic patient-specific mutations through gene knock-in technology, enabling preclinical evaluation of targeted therapies (such as PARP inhibitors for DNA repair-deficient tumors). It also supports synthetic lethality studies, revealing vulnerabilities that can be used for precision oncology through combinatorial gene editing. Beyond oncology, this tool also aids in gene function validation (e.g., detecting epithelial-mesenchymal transition (EMT) regulators) and biomarker discovery through transcriptomic profiling of edited clones.